文献速递药物相互作用

胃pH变化或食物摄入不影响瑞博西利生物利用度:计算机模拟与临床评估

Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations.
PubMed 文献 · Clin Pharmacol Ther · 2017-12-08

瑞博西利为CDK4/6抑制剂,用于HR+/HER2-晚期乳腺癌一线治疗,无胃pH升高剂或食物限制。研究通过生物相关介质溶解度、PBPK建模、临床试验数据NCA和PopPK分析多途径评估PPI影响,表明胃pH变化不影响瑞博西利PK,支持说明书无需专门DDI试验即可声明无影响;临床试验证实高脂餐与空腹暴露生物等效。

要点

  • 胃pH升高剂(如PPI)不影响瑞博西利药代动力学,无需调整给药。
  • 高脂餐与空腹状态下瑞博西利暴露生物等效,饮食无限制。
  • 多途径证据支持说明书声明,无需专门药物相互作用试验。

核心结论

  • 胃pH变化不影响瑞博西利药代动力学,胃pH升高剂或食物摄入无需限制。
  • 高脂餐与空腹状态下瑞博西利暴露生物等效,支持无饮食限制的给药。

研究设计与样本

  • 采用生物相关介质溶解度、PBPK建模、临床试验数据非房室分析(NCA)和群体药代动力学(PopPK)分析多途径评估。

主要发现

  • 多途径方法表明胃pH变化对瑞博西利PK无影响。
  • 临床试验证实高脂餐与空腹瑞博西利暴露生物等效。

关键数值与推荐

  • 瑞博西利说明书可声明胃pH改变剂对吸收无影响,无需专门DDI试验。
  • 高脂餐与空腹给药生物等效,支持无饮食限制。

临床怎么用

  • 瑞博西利可与胃pH升高剂(如PPI)合用,无需调整剂量或间隔给药。
  • 患者无需因饮食限制服药时间,可随餐或空腹服用,有助于提高依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ribociclib (KISQALI), a cyclin-dependent kinase 4/6 inhibitor approved for the first-line treatment of HR+/HER2- advanced breast cancer with an aromatase inhibitor, is administered with no restrictions on concomitant gastric pH-elevating agents or food intake. The influence of proton pump inhibitors (PPIs) on ribociclib bioavailability was assessed using 1) biorelevant media solubility, 2) physiologically based pharmacokinetic (PBPK) modeling, 3) noncompartmental analysis (NCA) of clinical trial data, and 4) population PK (PopPK) analysis. This multipronged approach indicated no effect of gastric pH changes on ribociclib PK and served as a platform for supporting ribociclib labeling language, stating no impact of gastric pH-altering agents on the absorption of ribociclib, without a dedicated drug-drug interaction trial. The bioequivalence of ribociclib exposure with or without a high-fat meal was demonstrated in a clinical trial. Lack of restrictions on ribociclib dosing may facilitate better patient compliance and therefore clinical benefit.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Samant TS, Dhuria S, Lu Y, et al. Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations. Clin Pharmacol Ther. 2017. PMID: 29134635. doi:10.1002/cpt.940

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。